PMID

Data

Article Title

Organization

2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.

Astrazeneca Pharmaceuticals

Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.

Merck Research Laboratories

Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review.

University of Catania

Recent developments on synthesis and biological activities of ?-carboline.

Northwest A&F University

Methyl-containing pharmaceuticals: Methylation in drug design.

Xenon Pharmaceuticals

Design and synthesis of 6-methylpyridin-2-one derivatives as novel and potent GluN2A positive allosteric modulators for the treatment of cognitive impairment.

Takeda Pharmaceutical

Squaric acid analogues in medicinal chemistry.

Palacky University Olomouc

Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).

Nanjing University of Chinese Medicine

Discovery of Pyrazolo[1,5-a]pyrazin-4-ones as Potent and Brain Penetrant GluN2A-Selective Positive Allosteric Modulators Reducing AMPA Receptor Binding Activity.

Takeda Pharmaceutical

Advancements in the development of multi-target directed ligands for the treatment of Alzheimer's disease.

Central University of Punjab

Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.

Central South University

Orally efficacious NR2B-selective NMDA receptor antagonists.

Merck Research Laboratories

Parallel synthesis of a series of subtype-selective NMDA receptor antagonists.

Parke-Davis Pharmaceutical Research

Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases.

Palack£

Ketamine esters and amides as short-acting anaesthetics: Structure-activity relationships for the side-chain.

University of Auckland

Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer's disease.

Jining Medical University

Multi-target design strategies for the improved treatment of Alzheimer's disease.

China Pharmaceutical University

Improving the inhibitory activity of arylidenaminoguanidine compounds at the N-methyl-D-aspartate receptor complex from a recursive computational-experimental structure-activity relationship study.

University of Kentucky

Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

Rugen Holdings (Cayman)

Oxysterols and methods of use thereof

Sage Therapeutics

3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists

Rugen Holdings (Cayman)

C7 substituted oxysterols and methods of use thereof

Sage Therapeutics

Oxysterols and methods of use thereof

Sage Therapeutics

3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists

Rugen Holdings (Cayman)

Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists

Rugen Holdings (Cayman)

N-arylmethyl sulfonamide negative modulators of NR2A

Luc Therapeutics

3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists

Rugen Holdings (Cayman)

3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists

Rugen Holdings (Cayman)

Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists

Rugen Holdings (Cayman)